The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
General
Brick-and-mortar clinic in Baton Rouge with telemedicine elsewhere. Consultations are with licensed clinicians in the patient's state under the supervision of Medical Director Reena John, DO.